NCT02868073View on ClinicalTrials.gov

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 29, 2016

Primary Completion Date

October 5, 2016

Study Completion Date

October 1, 2017

Conditions
Norovirus Gastroenteritis
Interventions
BIOLOGICAL

VXA-G1.1-NN (high dose) Oral Vaccine Tablet

The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.

OTHER

VXA Placebo Tablets

The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.

BIOLOGICAL

VXA-G1.1-NN (low dose) Oral Vaccine Tablet

The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.

Trial Locations (1)

68502

Celerion, Inc., Lincoln

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT02868073 - Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine | Biotech Hunter | Biotech Hunter